GLP-1 may exert its outcomes through both receptor-dependent and receptor-independent mechanisms and through the actions of both the intact peptide and its metabolites [3]. GLP-1 receptor agonists have shown cardiovascular benefits as well as a reduction in albuminuria independent of glycemic control, causing a new dimension within the control of T2DM [4]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.